Precision Medicine Is Coming to the Masses

Precision Medicine Is Coming to the Masses by  for Casey Research

Rachel’s note: The pandemic is opening the door to some of the best investment opportunities of our lifetimes. And our friend and colleague, Jeff Brown, has homed in on one that we had to bring to your attention…

…Because it could lead you to 1,000% gains… in just one day.

Jeff’s a legendary tech investor… an insider who says that COVID-19 is ramping up the overlooked world of biotech.

He believes it’s just the beginning of a years-long bull market.

That’s why on August 5 at 8 p.m. ET, he’s hosting a free biotech “masterclass.” He’ll share everything he’s learned to help you invest smartly in this sector. But only if you reserve your free spot right here.

By Jeff Brown, editor, Exponential Tech Investor

Grace Wilsey couldn’t cry…

As a baby, she would lie limp in her parents’ arms, staring blankly into the distance.

Her seizures wouldn’t stop. Medical tests showed signs of liver damage. This was all before her second birthday.

Grace’s parents were beside themselves, as any parent would be. They traveled the country visit­ing specialists. They ran numerous tests, but no one could diagnose Grace’s condition.

“We’ve probably seen over 100 doctors,” Grace’s father said in 2014 when Grace’s symptoms were discovered.

None of them could provide an explanation.

Then, when their daughter turned two years old, the Wilseys tried something else. They had Grace’s entire genome sequenced.

A genome is an organism’s complete set of DNA, including all of its genes. “Genome sequencing” is the process of determining the complete DNA sequence. Think of it like creating a “genetic roadmap,” a complete blueprint of an organism’s genetic material.

What the test showed was astounding…

Grace Wilsey had a condition known as NGLY1 deficiency. In short, the little girl’s NGLY1 genes were mutated. They were like typos in her genet­ic makeup.

One of the gene mutations prevented the little girl from producing tears. At the time, the disor­der was so rare that only six people in the entire world had been diagnosed with it.

Now that the underlying cause is well understood, no time is wasted. Specific therapies can be developed to deal with this unusual genetic mutation.

The story I told you above is just one of millions. An estimated 280 million people suffer from a rare genetic disease. Many of them often live their lives undiagnosed.

But there is hope on the horizon.

The method that the Wilsey family used, genome sequencing, is experiencing exponential growth.

The cost of sequencing a human genome has plummeted. The speed of the sequencing tech­nology has grown exponentially.

And thanks to breakthroughs in genetic editing technology, we are on the verge of a complete transformation in medical care.

Thanks to this technology, diseases that were previously untreatable can be cured permanently.

And because of this tech, living to 100 and beyond will be the norm, not the exception. And we’ll experience a better quality of life along the way.

Imagine hiking the Grand Canyon for your 100th birthday. Or perhaps playing a round of golf at 110.

This is the future I see. And it presents one of the best investment opportunities of our lifetimes.

The Rise of Personalized Medicine

Today, most of us wait until we present symptoms of a disease before seeking treatment.

And if we get sick, we typically use a “one size fits all” approach to treat the disease. Currently, many treatments just address the symptoms, not the underlying causes.

That’s because scientists haven’t had the tools needed to cure the diseases permanently.

Continue Reading / Casey Research >>>


Sharing is caring!